arrow
J

Jakub Závada

first faculty of medicine
H指数:26
被引数:4,328

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Progression of sacroiliac joint structural lesions in axial spondyloarthritis: a longitudinal comparative study of MRI and radiography among European patients in routine clinical care

轴性脊柱关节炎患者骶髂关节结构病变的进展:欧洲常规临床护理中患者的MRI与放射影像纵向比较研究

2026-10-130
OAAI
Early haematologic response to anifrolumab in SLE: results from the European multicentre EFFORT-SLE study

抗RII型IFN单克隆抗体anifrolumab在系统性红斑狼疮患者中的早期血液学反应:欧洲多中心EFFORT-SLE研究的结果

2026-08-110
OAAI
Defining and validating a high specificity MRI cut-off for the radiographic part of the modified New York criteria in patients with axial spondyloarthritis

定义并验证改良纽约标准放射学部分的高特异性MRI截断值在轴性脊柱关节炎患者中的应用

2026-07-170
OA
Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK-pot Collaboration

利用机器学习预测类风湿关节炎6至24个月内的缓解:JAK-pot Collaboration的见解

2026-04-060
OAAI
Coding systems and monitoring practices across the ERN ReCONNET: insights from a comprehensive survey and unmet needs

编码系统与监测实践在ERN ReCONNET中的比较:来自全面调查的见解与未满足的需求

2026-03-300
OAAI
Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study): effect of regulatory warnings

2015年以来,在类风湿关节炎国际注册研究合作(“JAK-pot”研究)中,Janus Kinase抑制剂(JAKi)处方的演变:监管警告的影响

2026-02-120
PREAI
Defining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis

定义巴思强直性脊柱炎疾病活动指数(BASDAI)截断值,以评估欧洲多国轴性脊柱关节炎患者队列中的疾病活动状态。

2025-12-020
OAAI
Sacroiliac joint involvement in psoriatic arthritis – MRI, radiographic and clinical findings in 581 European routine care patients

银屑病关节炎中骶髂关节的受累情况——581例欧洲常规护理患者的MRI、放射影像学和临床发现

2025-10-030
OA
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

与生物制剂改善病情的抗风湿药物相比,接受JAK抑制剂治疗的风湿性关节炎患者发生主要不良心血管事件的发生率:来自国际注册研究合作的数据

2025-05-210
OAAI
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis
2025-05-011
OAAI
Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased
2025-02-280
OAAI
Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries
2024-08-190
OAAI
THE IMPACT OF SMOKING STATUS ON ONE-YEAR SECUKINUMAB RETENTION RATE IN 1,684 PATIENTS WITH PSORIATIC ARTHRITIS: REAL-WORLD RESULTS FROM THE EUROSPA COLLABORATION

吸烟状况对1,684例银屑病关节炎患者一年SECUKINUMAB保留率的影响:EUROSPA合作的真实世界结果

2024-06-010
PRE
BETTER DRUG RETENTION ON ANTI-IL17A COMPARED TO ANTI-TNF THERAPY DESPITE ITS INFERIOR EFFECT ON COMPOSITE JOINT INDEXES AND QUALITY OF LIFE IN PATIENTS WITH PsA-ANALYSIS FROMTHE CZECH BIOLOGICS REGISTRY ATTRA

与抗-TNF疗法相比,抗-IL17A药物在银屑病关节炎(PsA)患者中表现出更好的药物保留率,尽管其对复合关节指数和生命质量的影响较差——来自捷克生物制剂登记系统ATTRA的分析

2024-06-010
PRE
GLOBAL DISPARITIES IN BIOSIMILAR UPTAKE IN PATIENTS WITH RHEUMATOID ARTHRITIS

全球生物类似药在类风湿关节炎患者中的使用差异

2024-06-010
PRE
EFFICACY AND DRUG SURVIVAL OF IXEKIZUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS FROM THE CZECH BIOLOGICS REGISTRY ATTRA: IMPACT OF PRIOR SECUKINUMAB EXPOSURE

伊克替珠单抗(ixekizumab)在捷克生物制剂注册研究ATTRA中轴性脊柱关节炎患者的疗效和药物生存期:先前司库奇尤单抗(secukinumab)暴露的影响

2024-06-010
PRE
DIFFERENTIAL JOINT-LEVEL RESPONSES TO TNF INHIBITORS IN PSORIATIC ARTHRITIS: A COLLABORATIVE EUROPEAN OBSERVATIONAL COHORT STUDY

银屑病关节炎中肿瘤坏死因子抑制剂引起的关节水平差异反应:一项欧洲合作性观察队列研究

2024-06-010
PRE
PREDICTORS OF SECUKINUMAB TREATMENT RESPONSE AND CONTINUATION IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE EUROSPA RESEARCH COLLABORATION NETWORK

赛妥珠单抗治疗反应和持续性的预测因子:欧洲脊柱关节炎研究合作网络的结果

2024-06-010
PRE